ZYNYZ
PeakmAbBLAINTRAVENOUSINJECTABLEPriority Review
Approved
Mar 2023
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYNYZ (retifanlimab-dlwr) is a monoclonal antibody that blocks programmed death receptor-1 (PD-1), enabling immune system recognition and destruction of cancer cells. Approved in March 2023 by Incyte, it represents a checkpoint inhibitor in the competitive PD-1 antibody class. The drug is administered intravenously as an injectable biologic.
Peak
ZYNYZ is at peak commercial stage but faces significant competitive pressure (30/100), suggesting a mature but contested market requiring focused differentiation and efficient sales execution.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZYNYZ offers exposure to a mature, high-stakes oncology market and Incyte's specialized biologic platform, but the lack of linked job postings and modest spending relative to competitors suggests a lean, efficient team structure. Career growth will depend on successful differentiation strategy and market share capture in an increasingly crowded PD-1 space.
Brand Manager
Worked on ZYNYZ at Incyte? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.